Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Esophageal cancer: emerging therapeutics
JE Rogers, M Sewastjanow-Silva… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Esophageal cancer (EC) is a worldwide healthcare concern and represents an
aggressive malignancy. Squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are …
aggressive malignancy. Squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are …
Improving outcomes in patients with oesophageal cancer
The care of patients with oesophageal cancer or of individuals who have an elevated risk of
oesophageal cancer has changed dramatically. The epidemiology of squamous cell and …
oesophageal cancer has changed dramatically. The epidemiology of squamous cell and …
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction …
JV Reynolds, SR Preston, B O'Neill… - The Lancet …, 2023 - thelancet.com
Background The optimum curative approach to adenocarcinoma of the oesophagus and
oesophagogastric junction is unknown. We aimed to compare trimodality therapy …
oesophagogastric junction is unknown. We aimed to compare trimodality therapy …
Progenitor-like exhausted SPRY1+ CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable
esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers …
esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers …
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal …
K Kato, R Machida, Y Ito, H Daiko, S Ozawa, T Ogata… - The Lancet, 2024 - thelancet.com
Background Neoadjuvant therapy is the standard treatment for patients with locally
advanced oesophageal squamous cell carcinoma (OSCC). However, the prognosis remains …
advanced oesophageal squamous cell carcinoma (OSCC). However, the prognosis remains …
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
J Yin, J Yuan, Y Li, Y Fang, R Wang, H Jiao, H Tang… - Nature medicine, 2023 - nature.com
Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally
advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of …
advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of …
Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic …
F Ge, Z Huo, X Cai, Q Hu, W Chen, G Lin… - JAMA network …, 2022 - jamanetwork.com
Importance A considerable number of clinical trials of neoadjuvant immunotherapy for
patients with resectable esophageal cancer are emerging. However, systematic evaluations …
patients with resectable esophageal cancer are emerging. However, systematic evaluations …
[HTML][HTML] Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer
H Teng, Y Wang, X Sui, J Fan, S Li, X Lei, C Shi, W Sun… - Cancer Cell, 2023 - cell.com
Preoperative neoadjuvant chemoradiotherapy (nCRT) is a standard treatment for locally
advanced rectal cancer (LARC) patients, yet little is known about the mediators underlying …
advanced rectal cancer (LARC) patients, yet little is known about the mediators underlying …
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): a multicenter, phase 2 study
J Liu, J Li, W Lin, D Shao, L Depypere… - … journal of cancer, 2022 - Wiley Online Library
Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is
controversial, especially in the context of potential benefit of combining PD‐1 blockade with …
controversial, especially in the context of potential benefit of combining PD‐1 blockade with …
Advances in diagnosis and management of cancer of the esophagus
Esophageal cancer is the seventh most common malignancy worldwide, with over 470 000
new cases diagnosed each year. Two distinct histological subtypes predominate, and …
new cases diagnosed each year. Two distinct histological subtypes predominate, and …